Contribution of specific ceramides to obesity-associated metabolic diseases.

Hammerschmidt, Philipp; Brüning, Jens C

Hammerschmidt, Philipp; Brüning, Jens C.

Affiliation

Hammerschmidt P; Department of Neuronal Control of Metabolism, Max Planck Institute for Metabolism Research, Gleueler Strasse 50, 50931, Cologne, Germany.
Brüning JC; Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), University Hospital Cologne, Kerpener Strasse 26, 50924, Cologne, Germany.

Cell Mol Life Sci ; 79(8): 395, 2022 Jul 05.

Article in En | MEDLINE | ID: mdl-35789435

Subject(s)

Ceramides; Metabolic Diseases; Ceramides/metabolism; Humans; Obesity/complications; Signal Transduction; Sphingolipids/metabolism

Key words

Atherosclerosis; Ceramide acyl chain length; Diabetes; High-fat diet; Insulin resistance; Lipid signaling; Lipotoxicity; Metabolic disease treatment; Obesity; Sphingolipids

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ceramides / Metabolic Diseases Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Cell Mol Life Sci Journal subject: BIOLOGIA MOLECULAR Year: 2022 Type: Article Affiliation country: Germany

Fulltext

XML

PubMed Links

Search on Google